ESOC 2016: Bromodomain inhibitors - Bet what are BETs
ONCOTRANS 2017 - Eric Raymond - TGF-beta inhibition
ASCO-GI: The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors
ASCO-GI; Performance of 18-FDG-PET in the management of non-metastatic HIV+ anal squamous cell carcinoma (ASCC)
ESOC 2016: MET/HGF relevance for targeted therapy malignancies
New Targets & New Drugs in Hepatocellular carcinoma
Bridging the Gap Between Preclinical/Translational Data to Clinical Applications - Eric raymond - Tumour Models London 2016
The Efficacy and Safety of Sunitinib in Patients With Advanced Well‑Differentiated Pancreatic Neuroendocrine Tumors: Focus on Response Rate
Precision Medicine in Neuroendocrine Tumors: Targeted Drugs, Where Are We Heading To by Prof Eric Raymond oral presentation at 2016 ESMO Copenhagen
Biology of Anal Squamous Cell Carcinoma
Understanding the landscape of progress in the treatment of hepatocellular carcinoma
Multimodality Care for Patients with Cancer at Paris Saint-Joseph Hospital
Multimodality treatments for predominant liver metastases. Final 2016 barcelona by Eric Raymond